Medication info
Dapagliflozin Extended-Release Tablets 10/1000 mg (Dapagliflozin, Metformin)

Dapagliflozin Extended-Release Tablets 10/1000 mg (Dapagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Il-Yang Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped, bilaterally convex extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202300144 · Approved 2023.01.06 · Insurance code 641706500

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be initiated at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because such a change may cause changes in blood glucose control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Ingredients

Manufacturer
Il-Yang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used as an adjunct to dietary and exercise management to assist in glycemic control in adult patients with Type 2 diabetes who are using dapagliflozin and metformin together. Caution is needed regarding the occurrence of cardiovascular events in patients with insufficient glycemic control who have cardiovascular disease or risk factors. Refer to professional information before taking this medication. This drug helps improve glycemic control and aids in the management of Type 2 diabetes.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce the gastrointestinal adverse effects of metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medicine, the dose may be initiated at the patient's existing doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switched to it from other antihyperglycemic agents. Because such a change may cause changes in blood glucose control, any change in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).

Precautions

This medication comprises two components and is used in the treatment of diabetes. First, the metformin component included in this medication may rarely induce a serious condition known as lactic acidosis, which can be life-threatening; hence, caution is warranted. Additionally, when taken in conjunction with insulin or sulfonylureas, there is a risk of hypoglycemia. This drug should not be administered to certain patients, such as those with severely impaired kidney function, those in a state of dehydration, those with severe infections or cardiovascular issues, those with Type 1 diabetes, pregnant or breastfeeding women, and those with genetic lactose intolerance. Moreover, patients who are scheduled for surgery or tests using radiocontrast agents should halt the medication 48 hours prior to the test and resume only after confirming normal renal function. Patients with inadequate fluid volume or compromised renal function, elderly patients, and those with low blood pressure should consult a physician to thoroughly evaluate renal function and fluid status before taking this medication and continue to have their blood pressure symptoms and renal function monitored periodically during treatment. This drug can lead to various side effects such as genital infections, urinary tract infections, hypoglycemia, dehydration, dizziness, gastrointestinal disturbances, etc., so inform healthcare professionals immediately if symptoms occur. In particular, vitamin B12 deficiency can occur; therefore, periodic blood tests to check vitamin B12 levels are advisable for long-term use. Alcohol consumption may increase the risk of side effects associated with this medication; thus, excessive drinking should be avoided during treatment. Women who are pregnant or may become pregnant, as well as nursing mothers, should not use this medication, and it should be discontinued immediately upon confirmation of pregnancy. Elderly individuals are more likely to experience decreased renal function, thus monitoring dosage and renal function is necessary; this medication is not used in cases of severe renal impairment. In the event of overdose, there is no specific antidote available, and appropriate treatment should be initiated based on symptoms, and rapid dialysis may be necessary for metformin component overdose. Lastly, this medication should be stored out of reach of children and kept in the original container to prevent misuse and deterioration in quality.

Side effects

Vulvovaginitis, balanitis, genital infections, urinary tract infections, fungal infections, hypoglycemia, reduced fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, vulvar pruritus, genital pruritus, elevated hematocrit, decreased creatinine clearance from the kidneys, dyslipidemia, increased blood creatinine, elevated blood urea, weight loss, ketoacidosis, urosepsis, pyelonephritis, acute kidney injury, renal dysfunction, rash, diarrhea, nausea, vomiting, decreased vitamin B12, Guillain-Barré syndrome, bacterial pneumonia, sialadenitis, headache, facial paralysis, peripheral neuropathy, sensory disturbances, drowsiness, tremor, increased alanine aminotransferase, increased blood sugar, tendinitis, arthralgia, myalgia, myofascial pain syndrome, osteoarthritis, osteochondrosis, limb pain, periarticular inflammation, tendinopathy, trigger finger, weakness, fatigue, peripheral edema, swelling, pain, vitamin D deficiency, hyperglycemia, urethral syndrome, cough, hyperventilation, pruritus, benign prostatic hyperplasia, atrial fibrillation, palpitations, insomnia, neurogenic hearing loss, acute cholecystitis, chest pain, thermal burn, wrist fracture

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in an airtight container to protect it from air and moisture. It should also be kept at room temperature, which is safe between 1 and 30 degrees Celsius, avoiding excessively hot or cold environments.

Appearance and packaging

Appearance

Yellow, oval-shaped, bilaterally convex extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.